Immunovant IMVT
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Immunovant (IMVT) Business Model and Operations Summary
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).
Key Insights
Immunovant (IMVT) Core Market Data and Business Metrics
Latest Closing Price
$15.2Market Cap
$2.58 BillionPrice-Earnings Ratio
-6.85Total Outstanding Shares
169.86 Million SharesTotal Employees
207Dividend
No dividendIPO Date
June 21, 2019SIC Description
Biological Products, (no Disgnostic Substances)Primary Exchange
NASDAQHeadquarters
320 West 37th Street, New York, NY, 10018
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities, Continuing | $472.81 Million |
| Exchange Gains/Losses | $2.51 Million |
| Net Cash Flow | $203.01 Million |
| Net Cash Flow From Investing Activities, Continuing | $-659,000 |
| Net Cash Flow From Operating Activities | $-271.64 Million |
| Net Cash Flow, Continuing | $200.50 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Income/Loss | $-323.01 Million |
| Diluted Earnings Per Share | $-2.22 |
| Basic Average Shares | $439.60 Million |
| Net Income/Loss Available To Common Stockholders, Basic | $-323.01 Million |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
| Preferred Stock Dividends And Other Adjustments | $0 |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Other Comprehensive Income/Loss | $-107.63 Million |
| Comprehensive Income/Loss Attributable To Parent | $-321.61 Million |
| Comprehensive Income/Loss | $-321.52 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Equity Attributable To Noncontrolling Interest | $0 |
| Prepaid Expenses | $32.55 Million |
| Equity Attributable To Parent | $449.05 Million |
| Equity | $449.05 Million |
| Liabilities And Equity | $515.71 Million |
| Liabilities | $66.65 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||